Phosphate Binder Switch Found to Benefit Peritoneal Dialysis Patients
The percentage of patients with serum phosphorus levels of 5.5 mg/dL and below more than doubled to 37.8% after 6 months of treatment with sucroferric oxyhydroxide.
CHICAGO—A subset of peritoneal dialysis (PD) patients switched to the iron-based phosphate binder sucroferric oxyhydroxide experienced phosphorus control after 6 months, investigators reported at the American Society of Nephrology's Kidney Week 2016 meeting.
Linda H. Ficociello, PhD, and colleagues of Fresenius Medical Care North America in Waltham, Massachusetts, performed a retrospective analysis of 92 PD patients (average age 49.9 years) from Fresenius Kidney Care who switched to the binder. Results showed that the proportion of patients with serum phosphorus levels of 5.5 mg/dL and below increased significantly from 15.2% at baseline to 35.2% at 1–3 months and 37.8% at 4–6 months of treatment. Although 84.8% of patients had hyperphosphatemia to start (average serum phosphorus 6.4 mg/dL), the proportion with serum phosphorus of 5.6 to 7 mg/dL fell by 33% and 40% at 3 and 6 months, respectively.
In addition, patients had a lower pill burden over time. They needed an average of 9.9 pills daily at baseline, but this dropped to 4.2 and 4.4 at 1–3 months and 4–6 months after switching to sucroferric oxyhydroxide.
“Dialysis patients have a large pill burden—on average 19 pills/day--and approximately half of these pills are phosphate binders,” Dr Ficociello and colleagues explained. “Poor adherence to phosphate binder prescription is common and may be related to high pill burden.”
The study was funded by Fresenius Medical Care North America, the makers of sucroferric oxyhydroxide (Velphoro).
- Ficociello LH, Parameswaran V, Van Zandt CR, et al. Serum Phosphorus and Phosphate Binder Pills per Day in Peritoneal Dialysis Patients Switched to Sucroferric Oxyhydroxide as Part of Routine Care. Presented at: Kidney Week 2016. November 15-20, 2016. Chicago. Abstract FR-PO1065.